Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study to Assess the Effect of Supratherapeutic Doses of Iptacopan on Cardiac Conduction Parameters and Safety

Robert Schmouder, Noemi Kaetterer, Kenneth Kulmatycki, Prasanna Kumar Nidamarthy

Blood (2023) 142 (Supplement 1): 5644.

https://doi.org/10.1182/blood-2023-179648

Published: 2023

Journal Articles

A First-in-Human, Phase 1 Study to Assess the Pharmacodynamic Properties of Single-Dose Iptacopan (CLNP023X2101)

Robert Schmouder, Guido Junge, Prasanna Kumar Nidamarthy, Kenneth Kulmatycki

Blood (2023) 142 (Supplement 1): 4096.

https://doi.org/10.1182/blood-2023-179655

Published: 2023

Journal Articles

A Phase 1 Study to Evaluate the Pharmacokinetics of Single High Doses of Iptacopan

Robert Schmouder, Noemi Kaetterer, Kenneth Kulmatycki, Prasanna Kumar Nidamarthy

Blood (2023) 142 (Supplement 1): 2723.

https://doi.org/10.1182/blood-2023-179012

Published: 2023

Journal Articles

Dose-Exposure-Response Relationships of Biomarkers and Efficacy Measures with Iptacopan, a Complement Factor B Inhibitor, in Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) with or without Concomitant Anti-C5 Therapy

Antonio Risitano, Régis Peffault de Latour, Eng Soo Yap, Lily LL Wong, Bor-Sheng Ko, Sung-Soo Yoon, Alexander Roeth, Irina Baltcheva, Julie Milojevic, Niamh Fagan, Kenneth Kulmatycki, Prasanna K Nidamarthy, Guido Junge, Jun Ho Jang

Blood (2022) 140 (Supplement 1): 5803–5804.

https://doi.org/10.1182/blood-2022-160114

Published: 2022

Journal Articles

MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans

Blood (2019) 133 (13): 1507–1516.

https://doi.org/10.1182/blood-2018-10-880849

Published: 2019

Includes: Supplemental data

NARROW

A Phase 1 Study to Assess the Effect of Supratherapeutic Doses of Iptacopan on Cardiac Conduction Parameters and Safety

A First-in-Human, Phase 1 Study to Assess the Pharmacodynamic Properties of Single-Dose Iptacopan (CLNP023X2101)

A Phase 1 Study to Evaluate the Pharmacokinetics of Single High Doses of Iptacopan

Dose-Exposure-Response Relationships of Biomarkers and Efficacy Measures with Iptacopan, a Complement Factor B Inhibitor, in Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) with or without Concomitant Anti-C5 Therapy

MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans

Email alerts

ASH Publications

American Society of Hematology

A Phase 1 Study to Assess the Effect of Supratherapeutic Doses of Iptacopan on Cardiac Conduction Parameters and Safety

A First-in-Human, Phase 1 Study to Assess the Pharmacodynamic Properties of Single-Dose Iptacopan (CLNP023X2101)

A Phase 1 Study to Evaluate the Pharmacokinetics of Single High Doses of Iptacopan

Dose-Exposure-Response Relationships of Biomarkers and Efficacy Measures with Iptacopan, a Complement Factor B Inhibitor, in Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) with or without Concomitant Anti-C5 Therapy

MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only